HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales In Brief

This article was originally published in The Rose Sheet

Executive Summary

L'Oréal Q1: Consolidated sales rise 1.3% on a reported basis, or 5.4% like-for-like, to $4.5 bil. (€1=$1.22), French company reports April 8. Total cosmetics sales were up 1.7% at current exchange rates to $4.4 bil. Professional division grew 3% to $616.4 mil., and active cosmetics gained 1.7% to $330 mil., but other divisions, impacted by negative currency effects, did not fare as well, according to L'Oréal. Consumer business sales rose a slight .5% to $2.5 bil., while luxury product sales increased .9% to $993.5 mil. North American sales were hit particularly hard due to currency, dropping 6.4% to $1.1 bil. However, "in the coming months a more favorable historical comparison should allow us to further improve our growth rate" and "the impact of currency fluctuations, once again strongly negative at the end of March, should be noticeably reduced over the rest of the year," according to CEO Lindsay Owen-Jones...

L'Oréal Q1: Consolidated sales rise 1.3% on a reported basis, or 5.4% like-for-like, to $4.5 bil. (€1=$1.22), French company reports April 8. Total cosmetics sales were up 1.7% at current exchange rates to $4.4 bil. Professional division grew 3% to $616.4 mil., and active cosmetics gained 1.7% to $330 mil., but other divisions, impacted by negative currency effects, did not fare as well, according to L'Oréal. Consumer business sales rose a slight .5% to $2.5 bil., while luxury product sales increased .9% to $993.5 mil. North American sales were hit particularly hard due to currency, dropping 6.4% to $1.1 bil. However, "in the coming months a more favorable historical comparison should allow us to further improve our growth rate" and "the impact of currency fluctuations, once again strongly negative at the end of March, should be noticeably reduced over the rest of the year," according to CEO Lindsay Owen-Jones....

Beiersdorf: Sales in the consumer business, which includes the Nivea and Eucerin brands, were up 6.9% adjusted for currency to $1.2 bil. (€1=$1.22) in the first quarter, firm reports. Division sales in the Americas grew 12.5%. Overall sales in the quarter advanced 6.5% adjusted for currency to $1.4 bil....

Clarins: Skin care sales grew 10% at constant exchange rates in the first quarter on the strength of the Super Restorative launch in the fourth quarter, Clarins reports April 8. As a result, beauty sales were flat at average exchange rates, but grew 4.2% on a like-for-like basis to $180.1 mil. (€1=$1.22). Fragrances, however, were negatively impacted by weak demand in Europe without new launches, the firm says, adding perfume sales declined 8.5% to $81.5 mil. on a reported basis and fell 1.4% on a like-for-like basis. Consolidated sales fell 2.8% on a reported basis and grew 2.3% on a like-for-like basis to $261.7 mil....

LVMH: Perfumes & Cosmetics sales in the first quarter fell 3% on a reported basis but grew 8% with comparable structure and exchange rates to $575.7 mil. (€1=$1.22), LVMH announces April 8. Christian Dior continued to drive sales, particularly in makeup, the company said, adding Guerlain , Fresh and Benefit also turned in strong performances. In the Selective Retailing division, sales benefited from Sephora's double-digit growth in Europe and a tourism revival in DFS, the firm says. Selective Retailing sales were up 2% on a reported basis and 11% organically to $920.1 mil. Consolidated sales increased 2% on a reported basis and 10% organically to $3.47 bil....

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel